Sandoz enters global deal to commercialise proposed biosimilar natalizumab2 Sep 2019
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.
Sandoz, a Novartis division and a global leader in biosimilars, has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Under the agreement, Polpharma Biologics will maintain responsibilities for development, manufacturing and supply of proposed biosimilar natalizumab. Sandoz will commercialize and distribute the medicine in all markets upon approval, through an exclusive global license.
Reference medicine natalizumab is a disease-modifying therapy (DMT) that was approved for use over 10 years ago, offering patients a valuable therapeutic option for treating RRMS.
In addition to the personal burden of MS for patients and families, affordability is a significant challenge for MS medicines globally. A recent report highlighted affordability as the most common challenge affecting access to MS therapy in 46% of the 90 countries included. Elsewhere it has been highlighted that providing access to DMTs for MS represents a considerable challenge for healthcare systems.
“Patient access to advanced medicines is important for all people diagnosed with a chronic disease, but the challenges are very pronounced for MS patients,” said Pierre Bourdage, ad interim Global Head of Biopharmaceuticals, Sandoz. “By nature, biosimilars create competition and cost savings, which are proven to make room in healthcare systems to treat more patients. With this agreement, we hope to build on our MS experience with small molecules and complex generics, and ultimately provide patients with expanded access to a DMT that healthcare systems may otherwise not be able to provide.”
The addition of proposed biosimilar natalizumab expands the Novartis/Sandoz portfolio across small molecules, complex generics, biosimilars, and innovator medicines enabling broad patient access to patented and off-patent medicines. In addition to entering complex and underserved areas such as MS, Sandoz is already helping patients in the areas of immunology, oncology and endocrinology. The division has a leading global portfolio with eight marketed biosimilars and a further 10+ in development.
New microbial air sampler addresses continuous monitoring
14 Nov 2019
The device supports the new EU GMP Annex 1 requirements.Read more
GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’
13 Nov 2019
China-US trade challenges has led to de-risking by pharma companies.Read more
Winners of the 16th Pharma Awards
11 Nov 2019
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.Read more
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies
8 Nov 2019
But personalized medicines will require new logistics and manufacturing systems.Read more
SGH Healthcaring unveils its new asthma spacer device
8 Nov 2019
Zephyr's revolutionary new design improves drug administration and simplifies treatment delivery for better observance.Read more
Recipharm expands Indian injectable dosage form capabilities
7 Nov 2019
Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.Read more
Aptar acquires a leader in drug delivery training devices and patient onboarding
6 Nov 2019
Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.Read more
Europe predicted to surpass the US in biologic manufacturing capacity by 2023
6 Nov 2019
Demand for biological manufacturing is growing faster than capacity growth.Read more
SP acquires Spain based global provider of complete sterile filling lines
5 Nov 2019
Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.Read more
Legacy recruits heavily to meet growing steriles demand
5 Nov 2019
Company to reach 250 employees by year end to meet growing drug product manufacturing demand.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation